SCHEMBL18879005

SCHEMBL18879005

CNc1ncnc2ncnn12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
ENPP1 P22413 2/20 0.34
KDM4E B2RXH2 6/20 0.34
GAA P10253 2/20 0.34
TSHR P16473 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
RCE1 Q9Y256 1/20 0.33
ATM Q13315 1/20 0.32
HPGD P15428 2/20 0.32
MAPK1 P28482 2/20 0.32
PKM P14618 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MAPT P10636 1/20 0.32
GLA P06280 1/20 0.32
LMNA P02545 1/20 0.32
CYP1A2 P05177 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAP4K4 O95819 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11916277 0.75 ALDH1A1 (0.41) ALDH1A1ENPP1KDM4EGAATSHR
SCHEMBL7894373 0.70 ALDH1A1 (0.47) ALDH1A1ENPP1KDM4EGAATSHR
SCHEMBL1537948 0.69 ALDH1A1 (0.45) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL9373335 0.65 LMNA (0.40) ALDH1A1ENPP1KDM4EGAATSHR
SCHEMBL12125309 0.65 ALDH1A1 (0.38) ALDH1A1ENPP1KDM4EGAATSHR
SCHEMBL12395328 0.65 ALDH1A1 (0.38) ALDH1A1ENPP1KDM4EGAATSHR
SCHEMBL21636968 0.65 YTHDC1 (0.30)
SCHEMBL18879024 0.64 YTHDC1 (0.33) LMNA
SCHEMBL11003960 0.63 ALDH1A1 (0.44) ALDH1A1ENPP1KDM4EGAATSHR
SCHEMBL22349723 0.63 PI4KA (0.33) MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170145009-A1 HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS EFFECTOR THERAPEUTICS, INC. 2017-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145009-A1 HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS MAP3K9, MAP3K19, MAP3K20 ALDH1A1 4542/4885ENPP1 3181/4885KDM4E 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.